About Kerri-Ann Millar
Kerri-Ann Millar is a chief financial officer at Syncromune.
Kerri-Ann Millar reports to the SEC as an officer of 1 public company: Cue Biopharma (CUE).
Kerri-Ann Millar first appears on SEC filings in 2018.
Experience
This experience comes from Kerri-Ann Millar's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kerri-Ann Millar in the role, so the role may have started earlier or lasted longer.
SY
Syncromune® Current
Chief Financial Officer
2025 – Present
Syncromune, Inc.
Chief Financial Officer
2025 – 2026 · Fort Lauderdale, FL
Develops investigational immune therapies for people with metastatic solid tumors.
CI
Cue Biopharma, Inc.
Chief Financial Officer
2017 – 2025 · Public company (CUE)
FT
Flexion Therapeutics
Corporate Controller
2014 – 2017
CU
Curis
Special Advisor, Finance
2005 – 2014
IT
Investors Bank & Trust
Director, Internal Audit
2003 – 2005
BH
Brown Brothers Harriman
Audit Manager, Assistant Vice President
1996 – 2003
PW
PwC
Senior Associate
1992 – 1996
Key Colleagues at Startups
The people Kerri-Ann Millar works with at each company, as listed on that company's latest Form D.
Syncromune, Inc. · Form D/A, May 11, 2026
JG
Joseph Gerardi
Executive officer
Jeffrey Cleland
Director
Douglas Watson
Lead Independent Director
JM
Joseph Maroon
Director
Stephen Dale
Chief Medical Officer
NS
Norman Schwartz
Director
Charles Link
Executive Chairman & Chief Innovation Officer
Eamonn Hobbs
President & Chief Executive Officer, director
Agustin Gago
Chief Operating Officer